{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT04261335",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "jRCT2043190112"
                        ],
                        "SecondaryIdDomain": [
                              "Japan Registry of Clinical Trials"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Incidence of composite endpoints is summarized.",
                              "Mortality is summarized.",
                              "Overall survival is summarized.",
                              "Duration of continuous respiratory support is summarized.",
                              "Duration of continuous use of vasopressors or pulmonary vasodilators is summarized.",
                              "Each composite scores are summarized. The higher scores mean a better outcome.",
                              "The developmental quotient is summarized. The higher scores mean a better outcome.",
                              "Presence of each event is summarized.",
                              "Presence of spasticity is summarized. Spasticity is the condition as below: increased muscle tone, or increased deep tendon reflex.",
                              "Presence of spasticity is summarized. The definition of epilepsy is the condition based on the International League Against Epilepsy.",
                              "MRI score is summarized. The scoring system is based on the report of Barkovich AJ, et al. (AJNR Am J Neuroradiol. 1998 ;19(1):143-9.) . The higher scores mean a worse outcome.",
                              "GMFCS score is summarized. The gross motor function can be categorized into 5 different level. The higher scores mean a worse outcome."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)",
                              "Mortality",
                              "Overall survival",
                              "Duration of continuous respiratory support",
                              "Duration of continuous use of vasopressors or pulmonary vasodilators",
                              "The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition",
                              "The developmental quotient in Kyoto Scale of Psychological Development 2001",
                              "Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words",
                              "Presence of spasticity",
                              "Presence of epilepsy",
                              "MRI score",
                              "Gross Motor Function Classification System (GMFCS) score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at 12, 26, 38, 52, and 78 weeks after administration",
                              "all of the clinical trial period (up to 44 months)",
                              "all of the clinical trial period (up to 44 months)",
                              "up to 78 weeks",
                              "up to 78 weeks",
                              "78 weeks after administration",
                              "78 weeks after administration",
                              "at 26, 38, 52, and 78weeks after administration",
                              "at 12, 26, 38, 52, and 78 weeks after administration",
                              "until 78 weeks after administration",
                              "at 2, and 78 weeks after administration",
                              "at 78 weeks after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04261335"
                        ]
                  }
            ]
      }
}